Our Network of Consultants

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

A PhD consultant in the biotechnology and life sciences industry with over 17 years of experience working internationally. Specializing in customer insights, market-driven product development and strategic marketing, with expertise in genomic medicine, gene therapy, cell therapy, nanomedicine, NGS, molecular diagnostics, oncology, and more. Held leadership positions in biotech and life sciences companies in Canada, US and UK, including Abcam, STEMCELL Technologies, Thermo Fisher Scientific, Cytiva/Danaher.

I have a a D.Phil. in Biochemistry from the University of Oxford with first author publication in Nature Immunology; an MSc from University of Toronto and a BSc (Honours) from University of British Columbia.

Consulting Services include:
Voice of Customer/Customer Insights
Market Driven Product Requirements
Value Propositions and Product Positioning
Product-Market fit
Competitor Landscape Assessments
Pricing Strategies
Go to Market Strategies

Innovator with extensive experience and a proven track record of developing successful corporate strategies that increase revenues in the Life Sciences industry. Creative visionary and change agent who identifies growth markets, business drivers and builds collaborative global and cross-functional relationships. Recognized for combining transformational business strategies with supporting business cases, operating plans, budgets, and programs.
EXPERTISE
Strategic Planning | M&A | Financial Analysis | Partnerships and IVs | Market Assessments | Negotiation | Deal Structuring | Due Diligence
APPLICATIONS
Flow cytometry, antibodies, reagents, dyes, instruments ( sorters and analyzers)